Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96KN8
UPID:
PLAT5_HUMAN
Alternative names:
Ca(2+)-independent N-acyltransferase; H-rev107-like protein 5; HRAS-like suppressor 5
Alternative UPACC:
Q96KN8; B7X6T1; F5GZ87; F5H4Y9
Background:
Phospholipase A and acyltransferase 5, also known as Ca(2+)-independent N-acyltransferase, H-rev107-like protein 5, and HRAS-like suppressor 5, is a multifunctional enzyme. It exhibits phospholipase A1/2 and acyltransferase activities, catalyzing the release of fatty acids from glycerophospholipids and transferring fatty acyl groups to form N-acylphosphatidylethanolamine, a precursor for N-acylethanolamines.
Therapeutic significance:
Understanding the role of Phospholipase A and acyltransferase 5 could open doors to potential therapeutic strategies.